Cargando…

Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea‐treated KCNJ11 neonatal diabetes

The incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP), are thought to be the main drivers of insulin secretion in individuals with sulfonylurea (SU)‐treated KCNJ11 permanent neonatal diabetes. The aim of this study was to assess for the first ti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bowman, Pamela, Patel, Kashyap A, McDonald, Timothy J, Holst, Jens J, Hartmann, Bolette, Leveridge, Maria, Shields, Beverley M, Hammersley, Suzie, Spaull, Steve R, Knight, Bridget A, Flanagan, Sarah E, Shepherd, Maggie H, Andrews, Rob C, Hattersley, Andrew T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688132/ https://www.ncbi.nlm.nih.gov/pubmed/37602910 http://dx.doi.org/10.1111/jdi.14071

Ejemplares similares

Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated KCNJ11 neonatal diabetes show predominance of non-K(ATP)-channel pathways
por: Bowman, Pamela, et al.
Publicado: (2019)

Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes
por: Babiker, Tarig, et al.
Publicado: (2016)

Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study
por: Bowman, Pamela, et al.
Publicado: (2018)

Psychiatric morbidity in children with KCNJ11 neonatal diabetes
por: Bowman, P., et al.
Publicado: (2016)

DEND Syndrome with Heterozygous KCNJ11 Mutation Successfully Treated with Sulfonylurea
por: Cho, Ja Hyang, et al.
Publicado: (2017)

Birth weight and diazoxide unresponsiveness strongly predict the likelihood of congenital hyperinsulinism due to a mutation in ABCC8 or KCNJ11
por: Hewat, Thomas I., et al.
Publicado: (2021)

Sulfonylurea Use During Entire Pregnancy in Diabetes Because of KCNJ11 Mutation: A Report of Two Cases
por: Gaal, Zsolt, et al.
Publicado: (2012)

Successful sulfonylurea treatment in a patient with permanent neonatal diabetes mellitus with a novel KCNJ11 mutation
por: Ahn, Sung Yeon, et al.
Publicado: (2015)

Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-α/Hepatocyte Nuclear Factor 4-α Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes
por: Besser, Rachel E.J., et al.
Publicado: (2011)

Management of sulfonylurea‐treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer
por: Shepherd, M., et al.
Publicado: (2017)

Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters
por: Knight, Bridget A, et al.
Publicado: (2016)

Incretin hormones and the satiation signal
por: Holst, J J
Publicado: (2013)

Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene
por: Al-Mahdi, Maria, et al.
Publicado: (2010)

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin
por: Shepherd, Maggie H., et al.
Publicado: (2018)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Visuomotor Performance in KCNJ11-Related Neonatal Diabetes Is Impaired in Children With DEND-Associated Mutations and May Be Improved by Early Treatment With Sulfonylureas
por: Shah, Reshma P., et al.
Publicado: (2012)

Five-Year Follow-Up for Women With Subclinical Hypothyroidism in Pregnancy
por: Shields, Beverley M., et al.
Publicado: (2013)

Bariatric Surgery: It’s Not Just Incretins!
por: Ferraz-Bannitz, Rafael, et al.
Publicado: (2021)

Assessing newborn body composition using principal components analysis: differences in the determinants of fat and skeletal size
por: Shields, Beverley M, et al.
Publicado: (2006)

Sulfonylurea Therapy in Two Korean Patients with Insulin-treated Neonatal Diabetes due to Heterozygous Mutations of the KCNJ11 Gene Encoding Kir6.2
por: Kim, Min Sun, et al.
Publicado: (2007)

Successful Transition From Insulin to Sulfonylurea Therapy in a Patient With Monogenic Neonatal Diabetes Owing to a KCNJ11 P333L Mutation
por: Philla, Katherine Q., et al.
Publicado: (2013)

Successful switching from insulin to sulfonylurea in a 3-month-old infant with diabetes due to p.G53D mutation in KCNJ11
por: Yoon, Jong Seo, et al.
Publicado: (2018)

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment
por: Song, Jingwen, et al.
Publicado: (2017)

MON-121 Successful Transition from Insulin to Sulfonylurea for a 26 Year Old Female with Neonatal Diabetes Secondary to KCNJ11 Gene Mutation
por: Ali, Sulaiman, et al.
Publicado: (2019)

Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation
por: Hajji, Sulaiman, et al.
Publicado: (2021)

The Role of Incretins on Insulin Function and Glucose Homeostasis
por: Holst, Jens Juul, et al.
Publicado: (2021)

Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants
por: Mancioppi, Valentina, et al.
Publicado: (2023)

Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk
por: Vedovato, Natascia, et al.
Publicado: (2016)

Lower Circulating B12 Is Associated with Higher Obesity and Insulin Resistance during Pregnancy in a Non-Diabetic White British Population
por: Knight, Bridget Ann, et al.
Publicado: (2015)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Carbohydrate‐induced weight gain models for diabetes research: Contribution of incretins and parasympathetic signal
por: Seino, Yusuke, et al.
Publicado: (2020)

Association of birthweight and penetrance of diabetes in individuals with HNF4A-MODY: a cohort study
por: Locke, Jonathan M., et al.
Publicado: (2021)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
por: Boer, Geke Aline, et al.
Publicado: (2020)

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet
por: Lee, Gendai
Publicado: (2022)

Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies
por: Steele, Anna M., et al.
Publicado: (2013)

Identifying clinical criteria to predict Type 1 diabetes, as defined by absolute insulin deficiency: a systematic review protocol
por: Shields, Beverley M, et al.
Publicado: (2012)

Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement
por: McDonald, Timothy J., et al.
Publicado: (2017)

A novel mutation KCNJ11 R136C caused KCNJ11-MODY
por: Chen, Yaning, et al.
Publicado: (2021)

Assessing whether genetic scores explain extra variation in birthweight, when added to clinical and anthropometric measures
por: Haulder, Maneka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2oupmcn5ktikldphqhb1apljo8